Compare Merck & Co., Inc. (MRK) vs Twilio Inc (TWLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Twilio Inc — how do they compare? Merck & Co., Inc. trades at $148.15 (market cap $366.28B), while Twilio Inc trades at $227.45 (market cap $34.69B). The key difference: Merck & Co., Inc. is far larger — about 10.6× Twilio Inc's market cap, and Merck & Co., Inc. pays a 2.29% dividend while Twilio Inc pays none. Which is the better fit depends on your goals.
| MRK | TWLO | |
|---|---|---|
Market Cap | $366.28B | $34.69B |
Sector | Health | Technology |
52-Week High | $156.43 | $255.95 |
52-Week Low | $77.60 | $100.09 |
Enterprise Value | $413.04B | $33.10B |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
Twilio (TWLO) trades at $225.89, down 3.04% today, showing strong fundamental momentum with three consecutive quarterly earnings beats and accelerating revenue growth from $3.8B in 2022 to $5.1B in 2025. The company has achieved profitability with a 20.62% net income margin in 2025, reversing previous losses, while technical indicators show a neutral stance with support at $222 and resistance at $230.
The outlook remains positive with 77% analyst buy ratings and a $266.31 consensus price target, representing 18% upside potential. Key risks include execution of AI strategy and competitive pressures in communications infrastructure, but strong free cash flow generation and strategic positioning for AI-driven customer engagement support the bullish case.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
